Investigating early signs of neurodegenerative diseases in patients with REM sleep behavior disorder.
North American Prodromal Synucleinopathy Consortium for RBD, Stage 2 (NAPS2)
This study is looking for people with REM sleep behavior disorder to see if early treatments can help slow down or prevent the development of conditions like dementia or Parkinson's disease.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-10866362 on NIH RePORTER |
What this research studies
This research focuses on individuals diagnosed with rapid eye movement (REM) sleep behavior disorder (RBD), who are at risk of developing neurodegenerative diseases such as dementia with Lewy bodies and Parkinson’s disease. The study aims to identify early interventions that could potentially slow or prevent the progression of these conditions. Participants will undergo comprehensive assessments and provide biofluid samples to support the development of neuroprotective treatments. By expanding the existing consortium, the research seeks to create a robust framework for future clinical trials targeting these early stages of neurodegeneration.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with REM sleep behavior disorder who are at risk for developing synucleinopathies.
Not a fit: Patients who do not have REM sleep behavior disorder or those already diagnosed with advanced neurodegenerative diseases may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to effective early interventions that may delay or prevent the onset of severe neurodegenerative diseases in at-risk individuals.
How similar studies have performed: Previous research has shown promise in early intervention strategies for neurodegenerative diseases, indicating that this approach could be beneficial.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Ju, Yo-El S — Washington University
- Study coordinator: Ju, Yo-El S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.